Indiana University Health’s Post

🔬 **Neoplastic Plasma Cells with Unique Inclusions** In the realm of hematopathology, certain rare cellular features can provide insight into plasma cell dyscrasias, such as multiple myeloma. Two intriguing findings include **azurophilic crystalline inclusions** and **Snapper-Schneid bodies**. ### Azurophilic Crystalline Inclusions - **Description**: These are crystalline structures within the cytoplasm of plasma cells, often staining a distinctive azurophilic color. - **Clinical Significance**: Their presence can be indicative of specific subtypes of multiple myeloma or other plasma cell disorders. ### Snapper-Schneid Bodies - **Characteristics**: Eosinophilic, rod-like structures that can be observed in the cytoplasm of affected plasma cells. - **Diagnostic Value**: Associated with particular myeloma variants, these bodies can aid in the differentiation and understanding of the disease. ### Implications for Diagnosis and Treatment Diagnosing these features typically involves: - **Bone Marrow Biopsy**: To identify the presence of atypical plasma cells. - **Laboratory Tests**: Including serum protein electrophoresis and immunofixation. - **Imaging**: Such as MRI or CT scans to assess bone involvement. ### Treatment Approaches Management strategies may include: - **Chemotherapy**: To reduce the burden of malignant cells. - **Targeted Therapy**: Utilizing drugs that specifically attack cancerous plasma cells. - **Stem Cell Transplantation**: Offering potential for long-term remission. ### Conclusion Recognizing and understanding these rare cellular features can enhance diagnostic accuracy and inform treatment plans, ultimately improving patient outcomes. 🔗 Connect with me for more insights into hematopathology and the latest research in plasma cell disorders! #Hematopathology #MultipleMyeloma #MedicalResearch #HealthcareInnovation #MedicalLaboratoryTechnology #Microbiology #Phlebotomy #LaboratoryTesting #DiagnosticTesting #HealthcareProfessional #MedicalTesting #ClinicalLaboratory #BiomedicalScience #HealthcareIndustry #MedicalScience #LaboratoryMedicine #ClinicalMicrobiology #InfectionControl #PhlebotomyTechnician #MedicalLabTechnician #MicrobiologyLab #ClinicalLab #HealthcareCareer #MedicalCareer #ScienceCareer #COVID19Testing #Virology #Bacteriology #Parasitology #MolecularDiagnosis #GeneticTesting #Cytology #Histopathology #Immunology #Serology

Great article about Sinaptica Therapeutics that is preparing for a Phase 3 trial in 2025 for its #neuromodulation therapy to slow #Alzheimers progression. This therapy combines transcranial magnetic stimulation (#TMS), #electroencephalography (#EEG), and #machinelearning. The system, targeting the precuneus, is a #noninvasive precision therapy designated as a Breakthrough Device by the FDA. Results from a Phase 2 study show significant slowing of Alzheimer's progression, with evidence of grey matter preservation and increased functional connectivity. CEO Ken Mariash and scientific co-founder Giacomo Koch highlight the therapy's potential to treat moderate Alzheimer's patients and emphasize the importance of early intervention. Sinaptica is consulting with the FDA and aims to elucidate the therapy's mechanism of action. The company plans to extend its research to #mildcognitiveimpairment and other #neurological disorders, considering its approach complementary to anti-amyloid drugs and emphasizing the need for combination therapies in treating Alzheimer's. Link: https://lnkd.in/e5eUjtUg

MSC-Derived Exosome Therapy: Advances and Clinical Trial Outcomes "The Rising Star of Regenerative Medicine: MSC-Derived Exosomes" Mesenchymal Stem Cell (MSC)-derived exosomes represent a major advancement in regenerative medicine, offering a non-cellular method for treating diverse diseases. These vesicles facilitate intercellular communication and support biological processes essential for regeneration by transporting proteins, RNA, and miRNAs. Key Clinical Trials 1.Chronic Kidney Disease (CKD): A trial in Egypt tested umbilical cord blood-derived MSC exosomes in a randomized, placebo-controlled setup, revealing their efficacy in slowing CKD progression. Patients received bi-weekly doses, improving renal function and decelerating the disease. 2.Cardiovascular Disease: This study combined MSC-derived exosomes with autologous mitochondrial transplantation in coronary artery bypass graft surgery, enhancing myocardial function and reducing complications, suggesting a new approach for cardiac repair. 3.Preeclampsia: Focusing on endothelial dysfunction in preeclampsia, MSC-derived exosomes improved placental health and maternal outcomes by promoting angiogenesis and enhancing endothelial cell function. Technological Progress 2024 also brought advancements in exosome isolation and characterization. Ultracentrifugation remains standard, while Tangential Flow Filtration (TFF) has gained importance for its efficiency and scalability. Challenges and Future Directions Despite successful clinical outcomes, issues like scalability and long-term safety persist, necessitating further innovation and comprehensive safety studies. Regulatory approvals also remain complex. Conclusion The 2024 clinical trials have deepened our understanding of MSC-derived exosome therapy, underscoring its potential in treating various conditions. Overcoming current challenges will be crucial for integrating these therapies into mainstream medical practice, providing new treatments for previously intractable conditions. Source : https://lnkd.in/dbkPK6mG #RegenerativeMedicine #MSCExosomes #ClinicalTrials2024 #StemCellResearch #HealthcareInnovation #Fibula #FibulaHEALTH #FibulaClinicalResearch #FibulaCRO #Health #Medical #Surgery #Oncology #Hematology #Immunology #Cartcell #Crispr #Cancer #CancerSurgery #Kanser #ClinicalResearch #ClinicalTrials #Pharma #who #CRO #Healthcare #WorldCancerDay #FightCancer #ClinicalTrials #CancerAwareness #CancerResearch #CancerCare #CancerPrevention #CancerTreatment #HealthEducation #GlobalSolidarity #InnovativeTreatments #CancerSurvivorship #CancerWarriors #BeatCancer

By combining bone marrow transplantation and the pioneering technology of machine learning, St. Jude scientists created the first version of a powerful prediction tool that could one day improve patient outcomes. The newly developed algorithm predicts patient survival more accurately than ever at 100 days, one year, and two years following a bone marrow transplant. This enables physicians to better identify which patients need additional clinical support. “One of the things that we have always struggled with is how to predict who’s going to have a bad outcome after transplantation,” said Akshay Sharma, MBBS, St. Jude Department of Bone Marrow Transplantation and Cellular Therapy. “If we can predict who will have these bad outcomes, we can do something about it.” Given the significant risks associated with bone marrow transplantation, physicians have created risk prediction models to identify who needs additional medical interventions because they are at the highest risk of developing these complications after transplant. Many of these models estimate mortality risk with only 50% accuracy because many of them only use data from a single point in time. The St. Jude algorithm takes data points at multiple times and examines far more variables than its predecessors to improve accuracy. The study demonstrated the possibility of improving early prediction of bad outcomes after bone marrow transplantation using machine learning. “We aim to uncover additional insights, piece together a clearer picture and develop enhanced solutions for the benefit of both clinicians and patients,” said Li Tang, PhD, St. Jude Department of Biostatistics. “It’s important to stress that this is just the outset.” Learn more: https://ow.ly/e5Xe50SUHGw

As ophthalmologists, we frequently see patients with corneal endothelial diseases. The promise of corneal endothelial cell therapy is being able to treat more patients with a less onerous recovery, with better outcomes and perhaps even earlier in their disease. We do not have anywhere near the number of corneas needed to treat all the world’s corneal blindness. With endothelial cell therapy, we will for the first time be able to make significant progress in reducing this number. https://lnkd.in/gHu34m29

Two monoclonal antibodies, aducanumab and lecanemab, have been approved by the US FDA for early Alzheimer's treatment in patients with confirmed β-amyloid pathology. Lecanemab even received full approval, marking a significant milestone. These anti-amyloid mAbs notably reduce total brain Aβ levels, contributing to a slowing of cognitive decline by approximately 30%, which is crucial for extending cognitive function and delaying severe dementia stages. This heralds a new era in Alzheimer's therapeutics with disease-modifying treatments. Further advancements aim for greater efficacy, safety, and convenience. Read the full article: https://lnkd.in/e6r2E4mv #Anogen #Alzheimers #Healthcare #MedicalBreakthrough #Neurology #FDAApproval 🔬✨

🔬 A new therapeutic for stroke, based on research from The University of Georgia, will soon enter clinical trials! The FDA recently cleared the new drug, known as AB126, to enter a Phase 1b/2a clinical trial. Unlike current treatments, it targets brain inflammation post-stroke, potentially revolutionizing stroke care. Developed from neural stem cells, it's versatile and may aid in ALS, Alzheimer's, and more. Read more about this groundbreaking research here: https://lnkd.in/gYK6a_T7

Understanding a cervical spinal cord injury (cSCI) is crucial for those impacted and their families. Dr Nasir Majeed, our Global Medical Director, explains the intricacies of cervical injuries, from symptoms and treatments to the journey towards recovery. Discover how our cutting-edge approach, including dual epidural stimulation and tailored stem cell therapies, is revolutionizing the recovery process for cSCI patients, including real-life patient stories of regained mobility and improved quality of life. https://lnkd.in/eSrPN2AR

Take a look at this case report relating to ADSC injections for knee osteoarthritis. ➡ Case report in Kuwasawa and Nihei Journal of Medical Case Reports (2021) focuses on adipose-derived stem cell therapy for knee osteoarthritis. 55-year-old Japanese woman with knee osteoarthritis underwent adipose-derived mesenchymal stem cell therapy in both knees. ➡ SYNAPSE VINCENT used for quantitative evaluation of cartilage pre- and post-treatment. ➡ Significant improvement in cartilage volume and reduction in defect area post-treatment observed. ➡ Highlights potential of adipose-derived stem cell intra-articular injections for osteoarthritis treatment. ➡ Discusses background of osteoarthritis, impact on patients' lives, and optimal management including regenerative medicine. Provides insights into adipose-derived mesenchymal stem cell therapy process and benefits. What are your thoughts? #osteoarthritis #stemcell #stemcelltherapy #orthopaedics #regenerativemedicine #allmedica #stemcellaustralia Allmedica

AI Meets Hematology: Pioneering Smarter, Accessible Care for All There’s growing excitement in hematology as machine learning (ML) and artificial intelligence (AI) make noticeable improvements in patient care. Thanks, Rakesh, for the post about St. Jude Children’s Research Hospital developing a prediction tool that uses machine learning to forecast patient survival after bone marrow transplantation more accurately. This is just one example of how AI is beginning to impact hematology. Other recent advancements include: ➡ Outcomes in hematologic malignancies: Deep learning methods are being used to analyze bone marrow cell morphologies with high precision and predict genetic mutations in acute myeloid leukemia (AML) from image data, thereby improving early detection and treatment strategies (https://lnkd.in/e58BFvsj) ➡ Improving Iron Deficiency Screening: A new ML approach could enhance how we screen for iron deficiency, making the process faster, more accurate, and more accessible (https://lnkd.in/edvT64-s) ➡ FDA Clearance for Digital Bone Marrow Aspirate Application: Scopio Labs has received FDA de novo clearance for an AI-based system to diagnose blood disorders and cancer. This is the first digital bone marrow application to allow remote analysis, offer a more detailed diagnostic process, and improve access to second opinions (https://lnkd.in/eugkiWYr). These developments suggest a promising future for hematology, with ML/AI likely to play an increasingly important role in enhancing patient care. I’m particularly interested in how these innovations could benefit patient care in underserved areas worldwide. #Hematology #MachineLearning #AI #HealthcareInnovation #Underserved